ClinicalTrials.gg
CompletedNCT02157376SUPUpdated Mar 10, 2017Results posted

Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients

A Phase 3 interventional study of Esomeprazole and Cimetidine in Stress Ulcer Prophylaxis, sponsored by AstraZeneca. Completed at 16 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Gastrointestinal Hemorrhage with a site in China — 8 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · China.

Enrollment
6th of 33
343 · median 101
Started
2014
the only one that year
Phase 3
4 of 40
1 open now
Registered
11th of 40
by date
Lead sponsor
2 of 40
AstraZeneca

Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 3, and was the 11th registered.

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

Browse Gastrointestinal Hemorrhage studies →

Open to participants now

8 of the 40 studies in Gastrointestinal Hemorrhage with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Gastrointestinal Hemorrhage with a site in China, or all of them as a file.
02

Study summary

The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.

Read the detailed description

Stress related upper Gastrointestinal (GI) bleedings are important events associated with morbidity and mortality among seriously ill patients. Data from the literature suggest that stress ulcer prevention with effective acid suppressive treatment can reduce bleeding events and is thus an important therapy in high-risk patients. Esomeprazole has the potential to reduce gastric acidity for prolonged periods of time adequate for both preventing mucosal damage and facilitating coagulation. This study is to reveal whether intravenous (iv) esomeprazole is effective in preventing upper gastrointestinal bleeding and if it is tolerated by Chinese seriously ill patients.

03

Conditions studied

  • Stress Ulcer Prophylaxis

Keywords

  • SUP
  • Upper GI bleeding
  • Seriously ill patients
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Critically ill patients
  2. Requirement for mechanical ventilation
  3. At least one major risk factor for stress ulcer related bleeding

Exclusion criteria

Exclusion Criteria:

  1. History of gastric or oesophageal surgery
  2. Evidence of active GI bleeding
  3. Advanced renal disease
  4. Treatment with any Proton Pump Inhibitors
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Esomeprazole active treatment

    iv esomeprazole 30 min intermittent infusions given for maximum 14 days

    Drug: Esomeprazole

  • Active comparator
    Cimetidine active treatment

    iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days

    Drug: Cimetidine

Interventions

  • iv esomeprazole 30 min intermittent infusions given for maximum 14 days

    Also known as: Nexium

  • iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days

    Also known as: Tagamet

06

What researchers measure

Primary outcomes

  1. The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase

    Criteria for a clinically significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that did not clear after NG or OG tube adjustment and 5 to 10 minutes of at least 100 ml lavage with room temperature normal saline-or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult- positive coffee ground material for at least eight consecutive hours that did not clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult- positive coffee ground material in at least three consecutive gastric aspirates within 2 to 4 hours (at least 60 ±20 minutes apart), that did not clear with at least 100 ml of lavage with room temperature normal saline.

    Time frame: 1-14 days

Secondary outcomes

  1. Proportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase

    Criteria for a significant upper GI bleeding as described in primary outcome measure or, Criteria for a non-significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that clear after NG or OG tube adjustment and 5 to 10 minutes of lavage with room temperature normal saline or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult - positive coffee ground material for at less than eight consecutive hours or that clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult - positive coffee ground material in less than three consecutive gastric aspirates within 2 to 4 hours (at least 60±20 minutes apart), or that clear with at least 100 ml of lavage with room temperature normal saline or, 3. Any clinical signs of hematemesis or melena or haematochezia judged (by the Investigator) to be from an upper GI source.

    Time frame: 1-14 days

07

Results

Posted Jan 23, 2017

Participant flow

Overall, 343 patients were enrolled from 27 centres in China. The first patient entered the study on 15 July 2014 and the last patient completed the study on 18 February 2016. Of the 343 patients enrolled into the study, 311 (90.7%) patients were randomised to treatment.

Participant flow — Overall Study
MilestoneEsomeprazoleCimetidine
Started155156
Completed133138
Not completed2218
Withdrew: Death104
Withdrew: Eligibility criteria not fulfilled01
Withdrew: Withdrawal by subject38
Withdrew: Not treated83
Withdrew: Investigator's misjudgement12

Outcome measures

PrimaryThe Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase

Criteria for a clinically significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that did not clear after NG or OG tube adjustment and 5 to 10 minutes of at least 100 ml lavage with room temperature normal saline-or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult- positive coffee ground material for at least eight consecutive hours that did not clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult- positive coffee ground material in at least three consecutive gastric aspirates within 2 to 4 hours (at least 60 ±20 minutes apart), that did not clear with at least 100 ml of lavage with room temperature normal saline.

Time frame:
1-14 days
Reported as:
Number · % of participants
The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase
% of participantsEsomeprazoleCimetidine
The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase2.74.6
Statistical analysis
  • Esomeprazole vs Cimetidine · Pearson's Chi-square · p = 0.393 · Risk difference (rd): 1.9 · 95% CI -2.8 to 6.5The difference in treatment group percentages is given by Cimetidine minus Esomeprazole.
SecondaryProportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase

Criteria for a significant upper GI bleeding as described in primary outcome measure or, Criteria for a non-significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that clear after NG or OG tube adjustment and 5 to 10 minutes of lavage with room temperature normal saline or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult - positive coffee ground material for at less than eight consecutive hours or that clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult - positive coffee ground material in less than three consecutive gastric aspirates within 2 to 4 hours (at least 60±20 minutes apart), or that clear with at least 100 ml of lavage with room temperature normal saline or, 3. Any clinical signs of hematemesis or melena or haematochezia judged (by the Investigator) to be from an upper GI source.

Time frame:
1-14 days
Reported as:
Number · proportion of participants
Proportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase
proportion of participantsEsomeprazoleCimetidine
Proportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase0.1090.105

Adverse events

Collected over AEs will be collected from the time of the first administration of IMP until the end of follow-up, up to 15 days. SAEs will be collected from signed inform consent until the end of follow-up, up to 15 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cimetidine—12/153 (7.8%)88/153 (57.5%)
Esomeprazole—14/147 (9.5%)85/147 (57.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCimetidineEsomeprazole
Septic shockInfections and infestations2/1533/147
Multi-organ failureGeneral disorders0/1532/147
Cerebral haemorrhageNervous system disorders1/1532/147
Cardio-respiratory arrestCardiac disorders0/1531/147
Cardiogenic shockCardiac disorders0/1531/147
Low cardiac output syndromeCardiac disorders0/1531/147
HypernatraemiaMetabolism and nutrition disorders0/1531/147
Systemic sclerosisMusculoskeletal and connective tissue disorders0/1531/147
Bronchial haemorrhageRespiratory, thoracic and mediastinal disorders0/1531/147
HypercapniaRespiratory, thoracic and mediastinal disorders0/1531/147
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCimetidineEsomeprazole
Lung infectionInfections and infestations31/15328/147
PyrexiaGeneral disorders25/15327/147
HypokalaemiaMetabolism and nutrition disorders19/15325/147
AnaemiaBlood and lymphatic system disorders15/15313/147
ConstipationGastrointestinal disorders14/1538/147
HyperglycaemiaMetabolism and nutrition disorders9/15313/147
HypoproteinaemiaMetabolism and nutrition disorders9/15311/147
Upper gastrointestinal haemorrhageGastrointestinal disorders10/1536/147
Hepatic function abnormalHepatobiliary disorders10/1539/147
HypernatraemiaMetabolism and nutrition disorders7/1539/147

Baseline characteristics

Among 311 randomised patients, 300 patients received randomised treatment: 147 patients in the esomeprazole treatment group and 153 patients in the cimetidine treatment group.

Age, Continuous
Age, Continuous(years)EsomeprazoleCimetidineTotal
Mean50.6 ± 11.850.1 ± 12.450.4 ± 12.1
Age, Customized
Age, Customized(participants)EsomeprazoleCimetidineTotal
<65 years131132263
>=65 years162137
Sex: Female, Male
Sex: Female, Male(Participants)EsomeprazoleCimetidineTotal
Female433881
Male104115219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EsomeprazoleCimetidineTotal
Asian/Chinese147153300
08

Study locations

16 sites
  • Research Site
    Baotou, China
  • Research Site
    Changsha, China
  • Research Site
    Chengdu, China
  • Research Site
    Chongqing, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Guilin, China
  • Research Site
    Haikou, China
  • Research Site
    Qingdao, China
  • Research Site
    Shanghai, China
  • Research Site
    Shenzhen, China
  • Research Site
    Tianjin, China
  • Research Site
    Wulumuqi, China
  • Research Site
    Xi'an, China
  • Research Site
    Xian, China
  • Research Site
    Zhanjiang, China
09

References and documents

Publications

  • Lou W, Xia Y, Xiang P, Zhang L, Yu X, Lim S, Xu M, Zhao L, Rydholm H, Traxler B, Qin X. Prevention of upper gastrointestinal bleeding in critically ill Chinese patients: a randomized, double-blind study evaluating esomeprazole and cimetidine. Curr Med Res Opin. 2018 Aug;34(8):1449-1455. doi: 10.1080/03007995.2018.1464132. Epub 2018 Apr 20. PubMed 29638148 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2014
First posted
Jun 6, 2014
Start
Jul 2014
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Jan 23, 2017
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02157376
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 6, 2014
Start date
Jul 2014
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Jan 23, 2017
Last update
Mar 10, 2017

Study contacts

Xinyu Qin
principal investigator · Professor and Chairman, Department of General Surgery,Zhongshan,Hospital, Fudan University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion